The Form 4 filing, an SEC report of insider stock activity, was submitted on October 26, 2026. The trades took place on October 23, 2026. The report names Martine A. Rothblatt, United Therapeutics' chairperson and CEO.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-23 |
| Date of Latest Transaction | 2026-10-23 |
| Buy/Sell | sell |
| Transaction Count | 11 |
| Shares Transacted | 9,500 |
| Price | $582.76 |
| Total Transaction Value | $5,536,235.04 |
| Insider | |
| Ticker Symbol | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider Name | ROTHBLATT MARTINE A |
| Insider Title | Chairperson & CEO |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 324,443 |
| Position Size Change | 2.84% |
| Filing | |
| Filing Date | 2026-10-26 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a share sale, reported with transaction code S. Martine A. Rothblatt sold UTHR shares in 11 transactions.
What was the average price of the transaction?
The average sale price was $582.76 per share, rounded to cents. Prices for each of the 11 separate transactions were not included in the available information.
How did this transaction affect the insider's holdings?
The sale reduced reported holdings by 9,500 shares, leaving 324,443 shares owned afterward. The shares sold made up 2.84% of the shares held before the sale.
What's the total transaction value?
The total value for all 11 transactions was $5,536,235.0411. That rounds to the $5,536,235.04 shown above.
Are there any special circumstances around this transaction?
The available information includes a Rule 10b5-1 reference. These trading plans set instructions in advance. The filing's footnote text was not available, so it is unclear whether a plan covered all 11 transactions. The plan's start date and trading schedule are also unknown. The reference alone does not explain the terms that applied to these sales.
For research purposes only; not investment advice.